Company Encyclopedia
View More
name
Minerva Neurosciences
NERV.US
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc.
1.901 T
NERV.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors

    Minerva Neurosciences Inc :MINERVA NEUROSCIENCES APPOINTS DR. INDERJIT KAUL TO THE COMPANY’S BOARD OF DIRECTORS

    Reuters·
    US
    NERV
    -4.90%
    Reuters·
    US
    NERV
    -4.90%

    Minerva Neurosciences Appoints New Director

    Minerva Neurosciences, Inc. announced the appointment of Inderjit Kaul, M.D., MPH as a new Class II director, effective November 14, 2025. Dr. Kaul's term will expire at the 2025 Annual Meeting of Stockholders. This appointment is part of a board expansion. Further details about Dr. Kaul's background and board role changes were not disclosed.

    TradingView·
    US
    NERV
    -4.90%
    TradingView·
    US
    NERV
    -4.90%

    Minerva Neurosciences Files Initial Beneficial Ownership Statement for Director Inderjit Kaul

    Minerva Neurosciences Inc. has filed a Form 3 with the SEC, listing Inderjit Kaul as a beneficial owner in his role as Director. This filing is informational and not financial advice.

    Reuters·
    US
    NERV
    -4.90%
    Reuters·
    US
    NERV
    -4.90%

    Minerva Neurosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting

    Minerva Neurosciences Inc. has announced its 2025 Annual Meeting of Stockholders will be held virtually on December 22, 2025. Stockholders can vote on proposals as outlined in the proxy statement. The announcement was made via EDGAR by Minerva Neurosciences Inc. on November 14, 2025.

    Reuters·
    US
    NERV
    -4.90%
    Reuters·
    US
    NERV
    -4.90%

    Minerva Neurosciences Reports Q3 2025 Financial Results

    Minerva Neurosciences (NERV) reported its Q3 2025 financial results, revealing a net loss of $9.76 million for the nine months ending September 30, 2025, compared to a net income of $5.71 million in the same period last year. The loss is attributed to increased R&D expenses and lack of significant other income. The company is focused on advancing its clinical trials for its lead product, roluperidone, despite facing regulatory challenges, including a Complete Response Letter from the FDA. Minerva plans to resubmit its NDA and is exploring strategic options to enhance shareholder value.

    Tip Ranks·
    US
    NERV
    -4.90%
    Tip Ranks·
    US
    NERV
    -4.90%
    © 2025 Longbridge｜Disclaimer